Listen
Reason for request
-
Clinical Benefit
| Low |
The actual benefit of OMNITROPE in children born small for gestational age with a birth weight and/or length of < -2 SD who failed to show catch-up growth (growth rate < 0 SD during the last year) by 4 years of age or later and with growth failure (current height less than or equal to -3 SD and parental adjusted height < -1 DS) is low. |
| Substantial |
The actual benefit of OMNITROPE in Turner syndrome is substantial. The actual benefit of OMNITROPE in chronic renal disease is substantial. The actual benefit of OMNITROPE in Prader-Willi syndrome is substantial. |
Clinical Added Value
| minor |
OMNITROPE provides a minor improvement in actual benefit (IAB IV) in the management of Turner syndrome, chronic renal insufficiency and Prader-Willi syndrome. |
| no clinical added value |
OMNITROPE does not bring about an improvement in actual benefit (IAB V) in the therapeutic strategy in children born small for gestational age. |
Documents
-
OMNITROPE 07122011 AVIS CT10063
-
Document court "L’hormone de croissance chez l’enfant non déficitaire, évaluation du service rendu à la collectivité"
-
Document long "L’hormone de croissance chez l’enfant non déficitaire, évaluation du Service Rendu à la Collectivité"
-
Synthèse d'avis HORMONES DE CROISSANCE
